1 Table of Contents 1 Table of Contents 4 1.1 List of Tables 5 1.2 List of Figures 8 2 Introduction 10 2.1 Blood Pressure Disorder Report Coverage 10 2.2 Hypertension - Overview 10 2.3 Hypotension - Overview 10 2.4 Pulmonary Arterial Hypertension - Overview 10 3 Therapeutics Development 11 3.1 Hypertension 11 3.2 Hypotension 32 3.3 Pulmonary Arterial Hypertension 35 4 Therapeutics Assessment 45 4.1 Hypertension 45 4.2 Hypotension 61 4.3 Pulmonary Arterial Hypertension 67 5 Companies Involved in Therapeutics Development 77 5.1 Hypertension 77 5.2 Hypotension 129 5.3 Pulmonary Arterial Hypertension 131 6 Dormant Projects 156 6.1 Hypertension 156 6.2 Hypotension 169 6.3 Pulmonary Arterial Hypertension 169 7 Discontinued Products 173 7.1 Hypertension 173 7.2 Pulmonary Arterial Hypertension 175 8 Product Development Milestones 176 8.1 Hypertension 176 8.2 Hypotension 187 8.3 Pulmonary Arterial Hypertension 197 9 Appendix 212 9.1 Methodology 212 9.2 Coverage 212 9.3 Secondary Research 212 9.4 Primary Research 212 9.5 Expert Panel Validation 212 9.6 Contact Us 213 9.7 Disclaimer 213

1.1 List of Tables Table 1: Number of Products under Development for Hypertension 11 Table 2: Number of Products under Development by Companies Hypertension 13 Table 3: Number of Products under Development by Universities/Institutes Hypertension 18 Table 4: Products under Development by Companies Hypertension 19 Table 5: Products under Development by Universities/Institutes Hypertension 30 Table 6: Number of Products under Development for Hypotension 32 Table 7: Number of Products under Development by Companies Hypotension 33 Table 8: Products under Development by Companies Hypotension 34 Table 9: Number of Products under Development for Pulmonary Arterial Hypertension 35 Table 10: Number of Products under Development by Companies Pulmonary Arterial Hypertension 37 Table 11: Number of Products under Development by Universities/Institutes Pulmonary Arterial Hypertension 39 Table 12: Products under Development by Companies Pulmonary Arterial Hypertension 40 Table 13: Products under Development by Universities/Institutes Pulmonary Arterial Hypertension 44 Table 14: Number of Products by Stage and Target Hypertension 46 Table 15: Number of Products by Stage and Mechanism of Action Hypertension 52 Table 16: Number of Products by Stage and Route of Administration Hypertension 58 Table 17: Number of Products by Stage and Molecule Type Hypertension 60 Table 18: Number of Products by Stage and Target Hypotension 62 Table 19: Number of Products by Stage and Mechanism of Action Hypotension 63 Table 20: Number of Products by Stage and Route of Administration Hypotension 65 Table 21: Number of Products by Stage and Molecule Type Hypotension 66 Table 22: Number of Products by Stage and Target Pulmonary Arterial Hypertension 68 Table 23: Number of Products by Stage and Mechanism of Action Pulmonary Arterial Hypertension 71 Table 24: Number of Products by Stage and Route of Administration Pulmonary Arterial Hypertension 75 Table 25: Number of Products by Stage and Molecule Type Pulmonary Arterial Hypertension 76 Table 26: Hypertension - Pipeline by A1M Pharma AB 77 Table 27: Hypertension - Pipeline by Acceleron Pharma Inc 77 Table 28: Hypertension - Pipeline by Ache Laboratorios Farmaceuticos SA 78 Table 29: Hypertension - Pipeline by Actelion Pharmaceuticals Ltd 78 Table 30: Hypertension - Pipeline by Aerogen Ltd 79 Table 31: Hypertension - Pipeline by Anavex Life Sciences Corp 79 Table 32: Hypertension - Pipeline by AnGes Inc 80 Table 33: Hypertension - Pipeline by Arena Pharmaceuticals Inc 80 Table 34: Hypertension - Pipeline by Ascendia Pharmaceuticals LLC 81 Table 35: Hypertension - Pipeline by Ascendis Pharma A/S 81 Table 36: Hypertension - Pipeline by AVEO Pharmaceuticals Inc 82 Table 37: Hypertension - Pipeline by Bayer AG 82 Table 38: Hypertension - Pipeline by Bial - Portela & Ca SA 83 Table 39: Hypertension - Pipeline by Bioblue Technologies Inc 83 Table 40: Hypertension - Pipeline by Biogen Inc 83 Table 41: Hypertension - Pipeline by Biolab Farmaceutica Ltda 84 Table 42: Hypertension - Pipeline by BioRestorative Therapies Inc 84 Table 43: Hypertension - Pipeline by Boryung Pharmaceutical Co Ltd 85 Table 44: Hypertension - Pipeline by Bristol-Myers Squibb Co 85 Table 45: Hypertension - Pipeline by Camurus AB 86 Table 46: Hypertension - Pipeline by Capricor Therapeutics Inc 86 Table 47: Hypertension - Pipeline by Celsion Corp 87 Table 48: Hypertension - Pipeline by Celtaxsys Inc 87 Table 49: Hypertension - Pipeline by Chiesi Farmaceutici SpA 88 Table 50: Hypertension - Pipeline by Chong Kun Dang Pharmaceutical Corp 88 Table 51: Hypertension - Pipeline by Chugai Pharmaceutical Co Ltd 89 Table 52: Hypertension - Pipeline by CJ HealthCare Corp 89 Table 53: Hypertension - Pipeline by Complexa Inc 89 Table 54: Hypertension - Pipeline by Corion Biotech Srl 901.2 List of Figures Figure 1: Number of Products under Development for Hypertension 11 Figure 2: Number of Products under Development by Companies Hypertension 12 Figure 3: Number of Products under Development by Universities/Institutes Hypertension 17 Figure 4: Number of Products under Development for Hypotension 32 Figure 5: Number of Products under Development by Companies Hypotension 33 Figure 6: Number of Products under Development for Pulmonary Arterial Hypertension 35 Figure 7: Number of Products under Development by Companies Pulmonary Arterial Hypertension 36 Figure 8: Number of Products under Development by Universities/Institutes Pulmonary Arterial Hypertension 39 Figure 9: Number of Products by Top 10 Targets Hypertension 45 Figure 10: Number of Products by Stage and Top 10 Targets Hypertension 45 Figure 11: Number of Products by Top 10 Mechanism of Actions Hypertension 51 Figure 12: Number of Products by Stage and Top 10 Mechanism of Actions Hypertension 51 Figure 13: Number of Products by Top 10 Routes of Administration Hypertension 57 Figure 14: Number of Products by Stage and Top 10 Routes of Administration Hypertension 57 Figure 15: Number of Products by Top 10 Molecule Types Hypertension 59 Figure 16: Number of Products by Stage and Top 10 Molecule Types Hypertension 59 Figure 17: Number of Products by Targets Hypotension 61 Figure 18: Number of Products by Stage and Targets Hypotension 61 Figure 19: Number of Products by Mechanism of Actions Hypotension 62 Figure 20: Number of Products by Stage and Mechanism of Actions Hypotension 63 Figure 21: Number of Products by Routes of Administration Hypotension 64 Figure 22: Number of Products by Stage and Routes of Administration Hypotension 64 Figure 23: Number of Products by Molecule Types Hypotension 65 Figure 24: Number of Products by Stage and Molecule Types Hypotension 66 Figure 25: Number of Products by Top 10 Targets Pulmonary Arterial Hypertension 67 Figure 26: Number of Products by Stage and Top 10 Targets Pulmonary Arterial Hypertension 67 Figure 27: Number of Products by Top 10 Mechanism of Actions Pulmonary Arterial Hypertension 70 Figure 28: Number of Products by Stage and Top 10 Mechanism of Actions Pulmonary Arterial Hypertension 70 Figure 29: Number of Products by Routes of Administration Pulmonary Arterial Hypertension 73 Figure 30: Number of Products by Stage and Routes of Administration Pulmonary Arterial Hypertension 74 Figure 31: Number of Products by Top 10 Molecule Types Pulmonary Arterial Hypertension 75 Figure 32: Number of Products by Stage and Top 10 Molecule Types Pulmonary Arterial Hypertension 76

A1M Pharma AB Acceleron Pharma Inc Ache Laboratorios Farmaceuticos SA Actelion Pharmaceuticals Ltd Aerogen Ltd Anavex Life Sciences Corp AnGes Inc Arena Pharmaceuticals Inc Ascendia Pharmaceuticals LLC Ascendis Pharma A/S AVEO Pharmaceuticals Inc Bayer AG BCO Pharma Ltd Bial - Portela & Ca SA Bioblue Technologies Inc Biogen Inc Biolab Farmaceutica Ltda BioRestorative Therapies Inc Boryung Pharmaceutical Co Ltd Bristol-Myers Squibb Co Camurus AB Capricor Therapeutics Inc Celsion Corp Celtaxsys Inc Cerecor Inc Chiesi Farmaceutici SpA Chong Kun Dang Pharmaceutical Corp Chugai Pharmaceutical Co Ltd CJ HealthCare Corp Complexa Inc Corion Biotech Srl Cumberland Pharmaceuticals Inc D. Western Therapeutics Institute Inc Daewon Pharm Co Ltd Daewoong Co Ltd Daewoong Pharmaceutical Co Ltd Daiichi Sankyo Co Ltd Denovo Biopharma LLC Eli Lilly and Co Esperion Therapeutics Inc FunPep Co Ltd Galectin Therapeutics Inc Gemphire Therapeutics Inc Gilead Sciences Inc GlaxoSmithKline Plc H. Lundbeck AS HanAll Biopharma Co Ltd Hanmi Pharmaceuticals Co Ltd Hypotension Idorsia Pharmaceutical Ltd Ildong Pharmaceutical Co Ltd Innopharmax Inc Insmed Inc Insys Therapeutics Inc Ionis Pharmaceuticals Inc Japan Tobacco Inc Jeil Pharmaceutical Co Ltd Johnson & Johnson KBP BioSciences Co Ltd La Jolla Pharmaceutical Company Leading BioSciences Inc Lee's Pharmaceutical Holdings Ltd Les Laboratoires Servier SAS LG Chem Ltd LinXis BV Liquidia Technologies Inc MannKind Corp Marina Biotech Inc Merck & Co Inc Mezzion Pharma Co Ltd N4 Pharma Plc Nippon Shinyaku Co Ltd Nissan Chemical Industries Ltd Northern Therapeutics Inc Novartis AG Omeros Corp Orion Corporation Peloton Therapeutics Inc Pfizer Inc PhaseBio Pharmaceuticals Inc Pulmokine Inc Pulmonary Arterial Hypertension Quantum Genomics SA Reata Pharmaceuticals Inc Relief Therapeutics Holding AG Relypsa Inc Renova Therapeutics Inc Respira Therapeutics Inc Reviva Pharmaceuticals Inc rEVO Biologics Inc Roivant Sciences Ltd Rottapharm Biotech Srl Sanofi Sarfez Pharmaceuticals Inc Serodus ASA Shanghai Pharmaceutical Co Ltd SJT Molecular Research SL SteadyMed Therapeutics Inc Suda Pharmaceuticals Ltd Sumitomo Dainippon Pharma Co Ltd Sun Pharma Advanced Research Company Ltd Takeda Pharmaceutical Co Ltd Target Medicals LLC The Medicines Company Theracos Inc Theravance Biopharma Inc Toray Industries Inc TrioxBio Inc United Therapeutics Corp Vascular BioSciences VG Life Sciences Inc Vicore Pharma AB Vivus Inc XuanZhu Pharma Co Ltd Yuhan Corp